https://orcid.org/0000-0002-0008-3104
References
- Baylis O, Figueiredo F, Henein C, Lako M, Ahmad S. 13 Years of cultured limbal epithelial cell therapy: A review of the outcomes. J Cell Biochem. 2011;112(4):993–1002. doi:10.1002/jcb.23028
- Rama P, Bonini S, Lambiase A, et al. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. Transplantation. 2001;72(9):1478–1485. doi:10.1097/00007890-200111150-00002
- Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med. 2010;363(2):147–155. doi:10.1056/NEJMoa0905955
- Beare JDL. Eye injuries from assault with chemicals. Br J Ophthalmol. 1990;74(9):514–518. doi:10.1136/bjo.74.9.514
- European Medicines Agency. First stem-cell therapy recommended for approval in EU; 19th December 2014 [Internet]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/12/news_detail_002239.jsp&mid=WC0b01ac058004d5c1. accessed August 6, 2018.
- Milazzo G, De Luca M, Pellegrini G. Holoclar: first of its kind in more ways than one. Cell Gene Ther Insights. 2016;2(2):183–197. doi:10.18609/cgti.2016.023
- European Medicines Agency 1995–2015 Working together for safe and effective medicines [Internet]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000628.jsp&mid=WC0b01ac058087addd. Accessed 6 August 2018.
- Dolan P. Modeling valuations for EurQol health states. Med Care. 1997;35(11):1095–1108. doi:10.1097/00005650-199711000-00002
- Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure from the SF-36. J Health Econ. 2002;21(2):271–292. doi:10.1016/S0167-6296(01)00130-8
- Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York: OUP; 2000.
- Longworth L, Yang Y, Mulhern B, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1–224. doi:10.3310/hta18090
- Yang Y, Rowen D, Brazier J, et al. Preference-Based Assessments: an Exploratory Study to Test the Impact on Three ‘Bolt-On’ Items to the EQ-5D. Value Health. 2015;18(1):52–60. doi:10.1016/j.jval.2014.09.004
- Luo N, Wang X, Ang M, et al. A Vision ‘Bolt-On’ Item Could Increase the Discriminatory Power of the EQ-5D Index Score. Value Health. 2015;18(8):1037–1042. doi:10.1016/j.jval.2015.08.002
- Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Netherlands: Springer; 2007.
- Watson V, Becker F, de Bekker-grob E. Discrete Choice Experiment Response Rates: A meta-analysis. Health Econ. 2017;26(6):810–817. doi:10.1002/hec.3354
- Ali S, Ronaldson S. Ordinal preference elicitation methods in health economics and health service research: using discrete choice experiments and ranking methods. Br Med Bull. 2012;103(1):21–44. doi:10.1093/bmb/lds020
- Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339(jul20 3):b2688. doi:10.1136/bmj.b2688
- Feeny D, Furlong W, Boyle M, Torrance GW. Multi-attribute health status classification systems: health Utilities Index. Pharmacoeconomics. 1995;7(6):490–502. doi:10.2165/00019053-199507060-00004
- Janssen M, Birnie E, Bonsel G. Quantification of the level descriptors for the standard EQ-5D three level system and a five level version according to 2 methods. Qual Life Res. 2008;17(3):463–473. doi:10.1007/s11136-008-9318-5
- Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–1736. doi:10.1007/s11136-011-9903-x
- Janssen MF, Bonsel G, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36(6):675–697. doi:10.1007/s40273-018-0623-8
- National Institute for Health and Care Excellence (NICE). Position statement on use of the EQ-5D-5L value set for England. 2019. https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l.accessed 22 July 2020.
- Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5(1):1–30. doi:10.1016/0167-6296(86)90020-2
- Bansback N, Brazier J, Tsuchiya A, Anis A. Using a discrete choice experiment to estimate health state utility values. J Health Econ. 2012;31(1):306–318. doi:10.1016/j.jhealeco.2011.11.004
- Martin AJ, Glasziou PP, Simes RJ, Lumley T. A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. Int J Technol Assess Health Care. 2000;16(1):137–147. doi:10.1017/S0266462300161124